XRCC4 rs1805377 polymorphism increases glioma risk in Asian populations

X-ray cross-complementing group 4 (XRCC4) is crucial for cells to maintain genetic stability thereby inflicting carcinogenesis. To date, epidemiologic findings have reached conflicting and ambiguous conclusions on the role of XRCC4 rs1805377 polymorphism in cancer risks. We made a comprehensive quantitative evaluation by performing a meta-analysis. Eligible publications assessing the association between XRCC4 rs1805377 polymorphism and cancer risks from PubMed, Embase and China national knowledge infrastructure (CNKI) databases were indentified. We used odds ratios (ORs) with 95% confidence intervals (CIs) to assess association strengths with the fixed-effect model or the random-effects model dependent on the heterogeneity. At the same time, subgroup analysis and sensitivity analysis were conducted. A total of 8 studies including 1911 cases and 2688 controls were included based on the search criteria. It was revealed by this meta-analysis that, in the Asian population, there was significant correlation between XRCC4 rs1805377 polymorphism and the risk of cancers (GG vs. AA: OR = 1.28, 95% CI = 1.05-1.57, Pheterogeneity = 0.392). In further stratified analyses, XRCC4 rs1805377 polymorphism was associated with increased glioma risk among Asians in homozygote comparison (GG vs. AA: OR = 1.59, 95% CI = 1.12-2.25, Pheterogeneity = 0.261). Significantly elevated cancers risk were also observed in population-based studies (GG versus AA: OR = 1.38, 95% CI = 1.11-1.72, Pheterogeneity = 0.571) and using other method studies (GG versus AA: OR = 1.63, 95% CI = 1.11-2.39, Pheterogeneity = 0.275). This meta-analysis indicated that XRCC4 rs1805377 polymorphism probably was associated with gliomas susceptibility in Asians.